SCHEMBL25554175

SCHEMBL25554175

CCOC(=O)C1CC(=O)/C(=C\N(C)C)C1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
KDM4E B2RXH2 4/20 0.46
KMT2A Q03164 4/20 0.46
MAPT P10636 5/20 0.40
MEN1 O00255 3/20 0.38
POLB P06746 2/20 0.38
HSD17B10 Q99714 2/20 0.38
ESR1 P03372 1/20 0.38
TSHR P16473 1/20 0.38
NR4A1 P22736 1/20 0.38
GAA P10253 1/20 0.37
HPGD P15428 1/20 0.37
HTT P42858 1/20 0.35
NFKB1 P19838 1/20 0.35
NFKB2 Q00653 1/20 0.35
RELA Q04206 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.34
CYP11B2 P19099 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30234127 0.90 ALDH1A1 (0.39) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL437950 0.87 PDK1 (0.41) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL437951 0.87 PDK1 (0.41) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL408733 0.87 PDK1 (0.41) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL30233472 0.84 ALDH1A1 (0.42) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL23284252 0.83 MAPT (0.44) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL14720181 0.83 MAPT (0.44) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL14720183 0.83 MAPT (0.44) ALDH1A1KDM4EKMT2AMAPTMEN1
SCHEMBL29226651 0.77 MAP1LC3B (0.40) KDM4EKMT2AMAPTMEN1POLB
SCHEMBL11081044 0.75 MAPT (0.34) ALDH1A1KDM4EKMT2AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2026-05-14 US disclosed
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity NOVARTIS PHARMA AG (CH) 2025-12-23 US disclosed
EP-4384503-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM Due, Inc. (US) 2024-06-19 EP disclosed
CN-118119595-A Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2024-05-31 CN disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-06-01 US disclosed
WO-2023018781-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2023-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260132109-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, IRF3, CGAS ALDH1A1 3829/4885KDM4E 4580/4885KMT2A 4396/4885
US-12503436-B2 Compounds and compositions for treating conditions associated with STING activity STING1, CGAS, IRF3 ALDH1A1 4654/4885KDM4E 3761/4885KMT2A 3772/4885
US-20230167057-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 ALDH1A1 4654/4885KDM4E 3761/4885KMT2A 3772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.